Englewood Lab (A950140) Q3 2024 earnings summary

Executive summary

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare and functional cosmetics, with a strong R&D focus and global certifications.

• Maintains a single consolidated subsidiary in Korea, fully owned and integrated into operations.

• Listed on KOSDAQ since 2016, with stable ownership and no recent changes in major shareholders.

Financial highlights

• 2024 Q3 consolidated revenue: $103.4M, down from $158.4M in 2023 and $117.3M in 2022 (USD basis).

• Operating income for 2024 Q3: $11.1M, compared to $22.1M in 2023 and $7.6M in 2022.

• Net income for 2024 Q3: $8.8M, down from $15.9M in 2023 and $5.6M in 2022.

• Basic EPS for 2024 Q3: $0.44, compared to $0.80 in 2023 and $0.28 in 2022.

• Cash and equivalents at Q3 end: $16.8M, up from $8.9M at 2023 year-end.

Outlook and guidance

• Focus on expanding into premium skincare markets and targeting global top-tier brands.

• Continued investment in R&D and regulatory compliance to maintain competitive edge.